Stockreport

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates [Yahoo! Finance]

Sana Biotechnology, Inc.  (SANA) 
PDF Early SC291 data from ongoing ARDENT trial in relapsed/refractory NHL and CLL suggest ability to dose safely, demonstrate the desired immune evasion profile, and early [Read more]